Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030

Encouragingclinical results across various metabolic, hematological and ophthalmicdisorders have inspired research groups across the world to focus their effortson the development of novel gene editing therapies. In fact, the gene therapypipeline has evolved significantly over the past few years, with three productsbeing approved in 2019 alone; namely Beperminogene perplasmid (AnGes),ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiplepipeline candidates in mid to late-stage (phase II and above) trials that areanticipated to enter the market over the next 5-10 years.

TheUSD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Market has been analyzed across the followingsegments:     

Keytherapeutic areas

·       Autoimmune disorders

·       Cardiovascular diseases

·       Genetic disorders

·       Hematological disorders

·       Metabolic disorders

·       Ophthalmic disorders

·       Oncological disorders

·       Others

Typeof vector

·       Adeno associated virus

·       Adenovirus

·       Herpes simplex virus type 1

·       Lentivirus

·       Plasmid DNA

·       Retrovirus

·       Vaccinia Virus

Typeof therapy

·       Ex vivo

·       In vivo

Typeof gene modification

·       Gene augmentation

·       Immunotherapy

·       Oncolytic therapy

·       Others

Routeof administration

·       Intraarticular

·       Intracerebellar

·       Intramuscular

·       Intradermal

·       Intravenous

·       Intravitreal

·       Intravesical

·       Subretinal

·       Others

Keygeographical regions

·       North America

·       Europe

·       Asia-Pacific

GetDetailed Sample Report: https://www.rootsanalysis.com/reports/268/request-sample.html

TheGene Therapy Market (3rd Edition), 2019-2030 report features the followingcompanies, which we identified to be key players in this domain:

·       Advantagene

·       Advaxis

·       BioMarin

·       bluebird bio

·       FKD Therapies

·       Freeline Therapeutics

·       GenSight Biologics

·       Gradalis

·       Inovio Pharmaceuticals

·       Marsala Biotech

·       Orchard Therapeutics

·       Pfizer

·       Sarepta Therapeutics

·       Spark Therapeutics

·       Tocagen

·       Transgene

·       uniQure Biopharma

·       VBL Therapeutics

·       ViroMed

Tableof Contents

1. Preface

2. Executive Summary

3. Introduction

4. Gene Delivery Vectors

5. Regulatory Landscape and Reimbursement Scenario

6. Competitive Landscape

7. Marketed Gene Therapies

8. Key Commercialization Strategies

9. Late Stage (Phase II/III and Above) Gene Therapies

10. Emerging Technologies

11. Promising Therapeutics Areas

12. Patent Analysis

13. Mergers and Acquisitions

14. Funding and Investment Analysis

15. Cost Price Analysis

16. Big Pharma Players: Analysis of Gene Therapy RelatedInitiatives

17. Market Forecast and Opportunity Analysis

18. Vector Manufacturing

19. Case Study: Gene Therapy Supply Chain

20. Conclusion

21. Interview Transcripts

22. Appendix 1: Tabulated Data

23. Appendix 2: List of Companies and Organizations

Requestfor Customization:

https://www.rootsanalysis.com/reports/268/request-customization.html    

AboutRoots Analysis

RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

ContactInformation

RootsAnalysis Private Limited

GauravChaudhary

+1(415) 800 3415